Market closed
Tenaya Therapeutics/$TNYA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tenaya Therapeutics
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
Ticker
$TNYA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
97
Website
TNYA Metrics
BasicAdvanced
$73M
-
-$1.31
2.84
-
Price and volume
Market cap
$73M
Beta
2.84
52-week high
$4.78
52-week low
$0.39
Average daily volume
2.2M
Financial strength
Current ratio
4.218
Quick ratio
3.846
Long term debt to equity
11.663
Total debt to equity
14.655
Management effectiveness
Return on assets (TTM)
-49.90%
Return on equity (TTM)
-95.69%
Valuation
Price to book
0.42
Price to tangible book (TTM)
0.42
Price to free cash flow (TTM)
-0.417
Growth
Earnings per share change (TTM)
-22.09%
3-year earnings per share growth (CAGR)
-31.64%
What the Analysts think about TNYA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Tenaya Therapeutics stock.
TNYA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TNYA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TNYA News
AllArticlesVideos
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
GlobeNewsWire·2 weeks ago
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
GlobeNewsWire·1 month ago
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tenaya Therapeutics stock?
Tenaya Therapeutics (TNYA) has a market cap of $73M as of May 09, 2025.
What is the P/E ratio for Tenaya Therapeutics stock?
The price to earnings (P/E) ratio for Tenaya Therapeutics (TNYA) stock is 0 as of May 09, 2025.
Does Tenaya Therapeutics stock pay dividends?
No, Tenaya Therapeutics (TNYA) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Tenaya Therapeutics dividend payment date?
Tenaya Therapeutics (TNYA) stock does not pay dividends to its shareholders.
What is the beta indicator for Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) has a beta rating of 2.84. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.